These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 1853824)
61. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Anzueto A; Baughman RP; Guntupalli KK; Weg JG; Wiedemann HP; Raventós AA; Lemaire F; Long W; Zaccardelli DS; Pattishall EN N Engl J Med; 1996 May; 334(22):1417-21. PubMed ID: 8618579 [TBL] [Abstract][Full Text] [Related]
62. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment. Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122 [TBL] [Abstract][Full Text] [Related]
63. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R; Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381 [TBL] [Abstract][Full Text] [Related]
64. Current surfactant use in premature infants. Suresh GK; Soll RF Clin Perinatol; 2001 Sep; 28(3):671-94. PubMed ID: 11570160 [TBL] [Abstract][Full Text] [Related]
65. Successful treatment of ARDS with two doses of synthetic surfactant. Heikinheimo M; Hynynen M; Rautiainen P; Andersson S; Hallman M; Kukkonen S Chest; 1994 Apr; 105(4):1263-4. PubMed ID: 8162762 [TBL] [Abstract][Full Text] [Related]
66. Prediction of the acute response to surfactant therapy by pulmonary function testing. Wallenbrock MA; Sekar KC; Toubas PL Pediatr Pulmonol; 1992 May; 13(1):11-5. PubMed ID: 1589306 [TBL] [Abstract][Full Text] [Related]
68. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Soll RF Cochrane Database Syst Rev; 2000; (2):CD000144. PubMed ID: 10796308 [TBL] [Abstract][Full Text] [Related]
69. Dexamethasone enhances the activity of rSP-C surfactant but not of exosurf in a rat model of the acute lung injury. Häfner D; Germann PG J Pharmacol Toxicol Methods; 1999 Sep; 42(1):39-48. PubMed ID: 10715602 [TBL] [Abstract][Full Text] [Related]
70. Surfactant replacement therapy in neonates less than 32 weeks gestation: effect on neonatal intensive care resource utilization. Diwaker K; Roberts S; John E J Paediatr Child Health; 1993 Dec; 29(6):434-7. PubMed ID: 8286159 [TBL] [Abstract][Full Text] [Related]
71. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Phibbs RH; Ballard RA; Clements JA; Heilbron DC; Phibbs CS; Schlueter MA; Sniderman SH; Tooley WH; Wakeley A Pediatrics; 1991 Jul; 88(1):1-9. PubMed ID: 2057244 [TBL] [Abstract][Full Text] [Related]
72. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. Goldman SL; Bosque E; McCann E; Lewis K J Pediatr; 1992 Feb; 120(2 Pt 2):S25-8. PubMed ID: 1735847 [TBL] [Abstract][Full Text] [Related]
74. On surfactant replacement therapy with Exosurf. Courtney SE Pediatr Pulmonol; 1992 May; 13(1):60-1. PubMed ID: 1589317 [No Abstract] [Full Text] [Related]
75. Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome. Hazan J; Chessex P; Piedboeuf B; Bourgeois M; Bard H; Long W J Pediatr; 1992 Feb; 120(2 Pt 2):S29-33. PubMed ID: 1735848 [TBL] [Abstract][Full Text] [Related]
76. Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Sood SL; Balaraman V; Finn KC; Britton B; Uyehara CF; Easa D Am J Respir Crit Care Med; 1996 Feb; 153(2):820-8. PubMed ID: 8564138 [TBL] [Abstract][Full Text] [Related]
77. [Biophysical models in investigations of exogenous surfactant activities on the surface tension and their theurapeutic effectiveness]. Todorov R; Iordanova A; Georgiev GA; Petkova Kh; Stoimenova E; Georgieva R; Khristova E; Vasiliev Kh; Lalchev Z Akush Ginekol (Sofiia); 2007; 46 Suppl 1():29-36. PubMed ID: 18175392 [TBL] [Abstract][Full Text] [Related]
78. Factors affecting the neonatal response to artificial surfactant. Skelton R; Jeffery HE J Paediatr Child Health; 1996 Jun; 32(3):236-41. PubMed ID: 8827542 [TBL] [Abstract][Full Text] [Related]
79. Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment. Pennefather PM; Tin W; Clarke MP; Fritz S; Strong NP Br J Ophthalmol; 1996 May; 80(5):420-4. PubMed ID: 8695563 [TBL] [Abstract][Full Text] [Related]
80. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation. Malathi I; Ng KC Ann Acad Med Singap; 1995 Nov; 24(6):781-4. PubMed ID: 8838980 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]